Literature DB >> 29523023

Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies.

Bani Ahluwalia1,2, Luiza Moraes1, Maria K Magnusson1, Lena Öhman1,3.   

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract with a multifactorial pathophysiology. Full comprehension of IBD pathology is still out of reach and, therefore, treatment is far from ideal. Nevertheless, components involved in IBD pathogenesis including environmental, genetic, microbial, and immunological factors are continuously being investigated and the improved knowledge contributes to the development of new therapies. In this article we review the aspects of the immunopathogenesis of IBD, with focus on mucosal immunity, and discuss mechanisms of action for current and emerging biological therapies.

Entities:  

Keywords:  Crohn’s disease; IBD; biological therapies; chronic inflammation; dysbiosis; dysregulated immune response; immunopathogenesis; ulcerative colitis

Mesh:

Year:  2018        PMID: 29523023     DOI: 10.1080/00365521.2018.1447597

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  37 in total

Review 1.  miRNAs in gastrointestinal diseases: can we effectively deliver RNA-based therapeutics orally?

Authors:  A K M Nawshad Hossian; Gerardo G Mackenzie; George Mattheolabakis
Journal:  Nanomedicine (Lond)       Date:  2019-11-18       Impact factor: 5.307

Review 2.  IL-1 and CD40/CD40L platelet complex: elements of induction of Crohn's disease and new therapeutic targets.

Authors:  Doha Anka Idrissi; Nezha Senhaji; Asmae Aouiss; Loubna Khalki; Youssef Tijani; Nabil Zaid; Fatima Zahra Marhoume; Abdallah Naya; Mounia Oudghiri; Mostafa Kabine; Younes Zaid
Journal:  Arch Pharm Res       Date:  2021-01-04       Impact factor: 4.946

3.  IBD therapeutics: what is in the pipeline?

Authors:  Alexandros Toskas; Ayesha Akbar
Journal:  Frontline Gastroenterol       Date:  2022-06-15

Review 4.  Role of interleukin-6-mediated inflammation in the pathogenesis of inflammatory bowel disease: focus on the available therapeutic approaches and gut microbiome.

Authors:  Arshia Shahini; Ali Shahini
Journal:  J Cell Commun Signal       Date:  2022-09-16       Impact factor: 5.908

Review 5.  Reproducing the human mucosal environment ex vivo: inflammatory bowel disease as a paradigm.

Authors:  Kenneth D Swanson; Evangelos Theodorou; Efi Kokkotou
Journal:  Curr Opin Gastroenterol       Date:  2018-11       Impact factor: 3.287

6.  Innate Immune Memory to Repeated Borrelia burgdorferi Exposure Correlates with Murine In Vivo Inflammatory Phenotypes.

Authors:  Quentin Bernard; Linden T Hu
Journal:  J Immunol       Date:  2020-11-09       Impact factor: 5.422

Review 7.  Role of Myeloid-derived suppressor cell (MDSC) in autoimmunity and its potential as a therapeutic target.

Authors:  Ehsan Nourbakhsh; Ali Mohammadi; Mohammad Salemizadeh Parizi; Atena Mansouri; Farnoosh Ebrahimzadeh
Journal:  Inflammopharmacology       Date:  2021-07-20       Impact factor: 4.473

Review 8.  T helper cell immunity in pregnancy and influence on autoimmune disease progression.

Authors:  Jonathon J Graham; Maria Serena Longhi; Michael A Heneghan
Journal:  J Autoimmun       Date:  2021-05-18       Impact factor: 7.094

9.  Preclinical Development of FA5, a Novel AMP-Activated Protein Kinase (AMPK) Activator as an Innovative Drug for the Management of Bowel Inflammation.

Authors:  Luca Antonioli; Carolina Pellegrini; Matteo Fornai; Laura Benvenuti; Vanessa D'Antongiovanni; Rocchina Colucci; Lorenzo Bertani; Clelia Di Salvo; Giorgia Semeghini; Concettina La Motta; Laura Giusti; Lorenzo Zallocco; Maurizio Ronci; Luca Quattrini; Francesco Angelucci; Vito Coviello; Won-Keun Oh; Quy Thi Kim Ha; Zoltan H Németh; Gyorgy Haskó; Corrado Blandizzi
Journal:  Int J Mol Sci       Date:  2021-06-13       Impact factor: 5.923

10.  Exploring the Mechanism of Berberine Intervention in Ulcerative Colitis from the Perspective of Inflammation and Immunity Based on Systemic Pharmacology.

Authors:  Yan Jiang; Li Zhao; Qing Chen; Lihong Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-09       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.